Company intelligence / Profile preview

AASraw Biochemical Technology

Ownership: Private
Employees: ~20
Development stage: Other

Overview

AASraw Biochemical Technology is an active commercial supplier of over 80 APIs and intermediates, mainly small molecules and hormones, with direct bulk production capabilities. Products reportedly have ≥98% purity and are produced under ISO9001, GMP, USP, EP, and BP regulations for global clients spanning pharma and research sectors[2][3][4][8]. No clinical-stage therapeutics; business is focused on custom synthesis, manufacturing, and bulk supply.

Therapeutic areas: EndocrinologyMetabolic DisordersMen's HealthOncologyNeurologyWomen's Health
Modalities: Small moleculeSteroid / HormoneAntibody-drug conjugateProteinOligonucleotidePeptidesNanoparticleBiologic
Industry: Contract Manufacturing Organization

Beyond the preview

Go deeper on AASraw Biochemical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AASraw Biochemical Technology.